Casein kinase 2-interacting protein-1, a novel Akt pleckstrin homology domain-interacting protein, down-regulates PI3K/Akt signaling and suppresses tumor growth in vivo

Cancer Research

Volumn 67, Issue 20, 2007, Pages 9666-9676

  Tokuda, Emi ^a,b   Fujita, Naoya ^a   Oh hara, Tomoko ^a   Sato, Shigeo ^a   Kurata, Atsuo ^a   Katayama, Ryohei ^a   Itoh, Toshiki ^c   Takenawa, Tadaomi ^c   Miyazono, Kohei ^b   Tsuruo, Takashi ^a  

^a CANCER CHEMOTHERAPY CENTER   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CASEIN KINASE II; LEUCINE ZIPPER PROTEIN; PLECKSTRIN; PROTEIN KINASE B; PROTEIN KINASE B BETA;

AMINO TERMINAL SEQUENCE; ARTICLE; CELL GROWTH; CONTROLLED STUDY; DIMERIZATION; DOWN REGULATION; EMBRYO; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TUMOR GROWTH; XENOGRAFT;

1-PHOSPHATIDYLINOSITOL 3-KINASE; AMINO ACID SEQUENCE; ANIMALS; BINDING, COMPETITIVE; CARRIER PROTEINS; CELL GROWTH PROCESSES; DIMERIZATION; DOWN-REGULATION; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; NEOPLASMS; PHOSPHATIDYLINOSITOLS; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 35448935143     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-1050     Document Type: Article

References (37)

1. Cheng JQ, Lindsley CW, Cheng GZ, Yang H, Nicosia SV. The Akt/PKB pathway: molecular target for cancer drug discovery. Oncogene 2005;24:7482-92.
2. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005;4:988-1004.
3. Wymann MP, Marone R. Phosphoinositide 3-kinase in disease: timing, location, and scaffolding. Curr Opin Cell Biol 2005;17:141-9.
4. Alessi DR, James SR, Downes CP, et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Bα. Curr Biol 1997;7:261-9.
5. Dong LQ, Liu F. PDK2: the missing piece in the receptor tyrosine kinase signaling pathway puzzle. Am J Physiol Endocrinol Metab 2005;289:E187-96.
6. Martelli AM, Nyakern M, Tabellini G, et al. Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. Leukemia 2006;20:911-28.
7. Stambolic V, Suzuki A, de la Pompa JL, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998;95:29-39.
8. Maehama T, Dixon JE. The tumor suppressor, PTEN/ MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 1998;273:13375-8.
9. Sable CL, Filippa N, Filloux C, Hemmings BA, Van Obberghen E. Involvement of the pleckstrin homology domain in the insulin-stimulated activation of protein kinase B. J Biol Chem 1998;273:29600-6.
10. Lemmon MA. Pleckstrin homology domains: not just for phosphoinositides. Biochem Soc Trans 2004; 32:707-11.
11. Pekarsky Y, Koval A, Hallas C, et al. Tcl1 enhances Akt kinase activity and mediates its nuclear translocation. Proc Natl Acad Sci U S A 2000;97:3028-33.
12. Laine J, Kunstle G, Obata T, Sha M, Noguchi M. The protooncogene TCL1 is an Akt kinase coactivator. Mol Cell 2000;6:395-407.
13. Teitell MA. The TCL1 family of oncoproteins: coactivators of transformation. Nat Rev Cancer 2005;5:640-8.
14. Bosc DG, Graham KC, Saulnier RB, et al. Identification and characterization of CKIP-1, a novel pleckstrin homology domain-containing protein that interacts with protein kinase CK2. J Biol Chem 2000;275:14295-306.
15. Safi A, Vandromme M, Caussanel S, et al. Role for the pleckstrin homology domain-containing protein CKIP-1 in phosphatidylinositol 3-kinase-regulated muscle differentiation. Mol Cell Biol 2004;24:1245-55.
16. Olsten ME, Canton DA, Zhang C, Walton PA, Litchfield DW. The pleckstrin homology domain of CK2 interacting protein-1 is required for interactions and recruitment of protein kinase CK2 to the plasma membrane. J Biol Chem 2004;279:42114-27.
17. Zhang L, Tie Y, Tian C, et al. CKIP-1 recruits nuclear ATM partially to the plasma membrane through interaction with ATM. Cell Signal 2006;18:1386-95.
18. Zhang L, Xing G, Tie Y, et al. Role for the pleckstrin homology domain-containing protein CKIP-1 in AP-1 regulation and apoptosis. EMBO J 2005;24:766-78.
19. kip1. Nature 2000;404:782-7.
20. kip1 promotes binding to 14-3-3 and cytoplasmic localization. J Biol Chem 2002; 277:28706-13.
21. Franke TF, Kaplan DR, Cantley LC, Toker A. Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. Science 1997; 275:665-8.
22. Stokoe D, Stephens LR, Copeland T, et al. Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. Science 1997;277:567-70.
23. Stephens L, Anderson K, Stokoe D, et al. Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B. Science 1998;279:710-4.
24. Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol 2001;3:245-52.
25. Maira SM, Galetic I, Brazil DP, et al. Carboxyl-terminal modulator protein (CTMP), a negative regulator of PKB/Akt and v-Akt at the plasma membrane. Science 2001;294:374-80.
26. Gao T, Furnari F, Newton AC. PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell 2005;18:13-24.
27. Remy I, Michnick SW. Regulation of apoptosis by the Ft1 protein, a new modulator of protein kinase B/Akt. Mol Cell Biol 2004;24:1493-504.
28. Tanaka M, Konishi H, Touhara K, et al. Identification of myosin II as a binding protein to the PH domain of protein kinase B. Biochem Biophys Res Commun 1999; 255:169-74.
29. Ingley E, Hemmings BA. PKB/Akt interacts with inosine-5′ monophosphate dehydrogenase through its pleckstrin homology domain. FEBS Lett 2000;478:253-9.
30. Kim AH, Yano H, Cho H, et al. Akt1 regulates a JNK scaffold during excitotoxic apoptosis. Neuron 2002;35: 697-709.
31. Hanada M, Feng J, Hemmings BA. Structure, regulation and function of PKB/AKT - a major therapeutic target. Biochim Biophys Acta 2004;1697:3-16.
32. Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3h regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 1998;12:3499-511.
33. Brognard J, Clark AS, Ni Y, Dennis PA. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 2001;61:3986-97.
34. Clark AS, West K, Streicher S, Dennis PA. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 2002;1:707-17.
35. Tsuruo T, Naito M, Tomida A, et al. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci 2003;94:15-21.
36. Kondapaka SB, Singh SS, Dasmahapatra GP, Sausville EA, Roy KK. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther 2003;2:1093-103.
37. Caron RW, Yacoub A, Li M, et al. Activated forms of H-RAS and K-RAS differentially regulate membrane association of PI3K, PDK-1, and AKT and the effect of therapeutic kinase inhibitors on cell survival. Mol Cancer Ther 2005;4:257-70.